While our study focused on the efficacy of the RIPK3-driven necroptotic safety switch using whole living cancer cells, which pose more safety concerns than other therapeutic cell types, it is crucial to acknowledge the potential of this safety switch to be implemented in a vast array of cells used in immunotherapies. This evidence concerns the gene RIPK3 and cancer.